Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kinetic Concepts' international sales surge as U.S. revenue dips

This article was originally published in The Gray Sheet

Executive Summary

International sales helped Kinetic Concepts Inc. achieve a 3.3% revenue gain in the first quarter over last year - to $485.8 million (or just below 1% at constant currency), the firm reported April 27. The total includes nearly $109.6 million in international sales, up 9.5% (or 1.3% at constant currency). But North American sales in KCI's Active Healing Solutions division, the company's largest, dipped 2% to $249.8 million during the quarter. A slowdown in U.S. demand for the firm's market-leading V.A.C. negative pressure wound therapy system was a factor behind the decline, CEO Catherine Burzik said, fueled in part by competition and more people either uninsured or on Medicaid due to high unemployment. The firm plans to fuel growth in part with a continued focus on Asian markets and new product launches, such as the next-generation V.A.C. Via, cleared by FDA in March. KCI's Regenerative Medicine division was one domestic bright spot, with U.S. sales of $78 million, up 18%. Globally, the latter division had revenue of $79 million, up 19.3%

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts